The role of laparoscopic retroperitoneal lymphadenectomy in the diagnosis of gastric cancer prevalence
Science and Innovations in Medicine · 2026-03-20 · 11 (2) · 123-128
DOI: 10.35693/sim699114 ↗At a glance
Journal article in Science and Innovations in Medicine, published online on 2026-03-20. Written by Mikael G. Abgaryan and 5 co-authors. 15 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Background
Preoperative examination of affected regional and distant lymph nodes is an important prognostic criterion when choosing treatment strategies for gastric cancer. In clinical practice, computed tomography (CT) with intravenous contrast is used to determine lymph node metastases, supplemented in controversial situations by positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG). In cases of inconclusive CT and PET/CT scan results, morphological verification of the retroperitoneal lymph nodes is required using minimally invasive techniques: core biopsy and/or laparoscopy with retroperitoneal lymphadenectomy. Aim: to evaluate the informative value and safety of laparoscopic retroperitoneal lymphadenectomy for the evaluation of retroperitoneal lymph nodes suspected of gastric cancer metastases. Material and methods. A total of 482 patients diagnosed with gastric and/or cardioesophageal junction cancer type II-III according to the Siewert classification were analyzed. They were treated at the Blokhin National Medical Research Center of Oncology from 2019 to 2023. If CT revealed retroperitoneal lymph nodes suspicious for metastases, 18F-FDG PET/CT was performed. If PET/CT data clearly showed metastasis, the patient was considered inoperable (M1). If PET/CT data revealed intact retroperitoneal lymph nodes, their morphological verification was not performed. In cases of questionable metabolic changes in the retroperitoneal lymph nodes, a decision was made to morphologically verify them using core biopsy under ultrasound or CT navigation. If core biopsy was not technically feasible, laparoscopy with retroperitoneal lymphadenectomy was performed.
Results
CT scans revealed retroperitoneal lymph nodes suspicious for metastases in 19/482 (3.9%) patients. 18F-FDG PET/CT scanning revealed foci of pathological radiopharmaceutical accumulation in retroperitoneal lymph nodes (M1) in 5/19 (26.3%) patients; metabolic and structural changes in the retroperitoneal lymph nodes were not detected in 6/19 (31.6%) patients. Questionable metabolic changes in the retroperitoneal lymph nodes were detected in 8/19 (52.6%) patients: core biopsy with ultrasound or CT navigation was performed in 3 (15.8%) patients, and biopsy was technically unfeasible in 5 patients. In one patient (5.3%), gastric cancer metastasis was confirmed by ultrasound-guided biopsy, and in two patients (10.5%), gastric cancer metastases were verified by retroperitoneal lymphadenectomy. No complications were recorded during core biopsy or retroperitoneal lymphadenectomy.
Conclusion
Laparoscopic retroperitoneal lymphadenectomy is an informative and safe minimally invasive method for morphological verification of retroperitoneal lymph nodes suspected of containing gastric cancer metastases.
Cite
APA
Abgaryan, M. G., Rusuna, E. I., Kalinin, A. E., Berdnikov, S. N., Tulin, P. E., & Stilidi, I. S. (2026). The role of laparoscopic retroperitoneal lymphadenectomy in the diagnosis of gastric cancer prevalence. Science and Innovations in Medicine, 11(2), 123-128. https://doi.org/10.35693/sim699114
Vancouver
Abgaryan MG, Rusuna EI, Kalinin AE, Berdnikov SN, Tulin PE, Stilidi IS. The role of laparoscopic retroperitoneal lymphadenectomy in the diagnosis of gastric cancer prevalence. Science and Innovations in Medicine. 2026;11(2):123-128. doi:10.35693/sim699114
BibTeX
@article{Abgaryan2026,
author = {Abgaryan, Mikael G. and Rusuna, Ekaterina I. and Kalinin, Aleksei E. and Berdnikov, Sergei N. and Tulin, Pavel E. and Stilidi, Ivan S.},
title = {The role of laparoscopic retroperitoneal lymphadenectomy in the diagnosis of gastric cancer prevalence},
journal = {Science and Innovations in Medicine},
year = {2026},
volume = {11},
number = {2},
pages = {123--128},
doi = {10.35693/sim699114}
}
EUVIMED